Chinese Journal of Antituberculosis ›› 2020, Vol. 42 ›› Issue (11): 1203-1208.doi: 10.3969/j.issn.1000-6621.2020.11.011
• Original Articles • Previous Articles Next Articles
GU Ji-xiu, LI Qing, MA ling, LI Yin-hua, WANG Dong-dong, SI Hong-yan()
Received:
2020-07-11
Online:
2020-11-10
Published:
2020-11-13
Contact:
SI Hong-yan
E-mail:1134864781@qq.com
GU Ji-xiu, LI Qing, MA ling, LI Yin-hua, WANG Dong-dong, SI Hong-yan. Application of next-generation sequencing technology in the diagnosis of drug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2020, 42(11): 1203-1208. doi: 10.3969/j.issn.1000-6621.2020.11.011
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2020.11.011
NGS技术检测 | 比例法药敏试验 | 敏感度 (%) | 特异度 (%) | 阳性预测值 (%) | 阴性预测值 (%) | 一致率 (%) | Kappa值 | |
---|---|---|---|---|---|---|---|---|
耐药(株) | 敏感(株) | |||||||
异烟肼 | 88.75 | 100.00 | 100.00 | 85.94 | 93.33 | 0.87 | ||
突变(株) | 71 | 0 | ||||||
未突变(株) | 9 | 55 | ||||||
乙胺丁醇 | 85.71 | 86.84 | 54.55 | 97.06 | 86.67 | 0.59 | ||
突变(株) | 18 | 15 | ||||||
未突变(株) | 3 | 99 | ||||||
利福平 | 84.72 | 96.83 | 96.83 | 84.72 | 90.37 | 0.81 | ||
突变(株) | 61 | 2 | ||||||
未突变(株) | 11 | 61 | ||||||
链霉素 | 73.91 | 96.97 | 96.23 | 78.05 | 85.19 | 0.71 | ||
突变(株) | 51 | 2 | ||||||
未突变(株) | 18 | 64 | ||||||
氧氟沙星 | 68.97 | 99.06 | 95.24 | 92.11 | 92.59 | 0.76 | ||
突变(株) | 20 | 1 | ||||||
未突变(株) | 9 | 105 |
药品名称 | 相关基因及位点 | 突变类型 | 突变菌株数 | 突变频率(%) | ||||
---|---|---|---|---|---|---|---|---|
异烟肼 | katG 315 | AGC-ACC | 60 | 84.51 | ||||
katG 315 | AGC-ATC | 4 | 5.63 | |||||
katG 297 | GGC-GTC | 1 | 1.41 | |||||
inhA+katG 315 | AGC-TGC+AGC-ACC | 1 | 1.41 | |||||
inhA+katG 315 | GGC-GCC+AGC-ACC | 1 | 1.41 | |||||
inhA+katG 315 | GAG-GGG+AGC-ACC | 1 | 1.41 | |||||
inhA+katG 315 | ACA-GCA+AGC-ACC | 2 | 2.82 | |||||
ahpC+katG 142 | GGC-GAC+GAC-GCC | 1 | 1.41 | |||||
合计 | 71 | 100.00 | ||||||
乙胺丁醇 | embB 306 | ATG-GTG | 20 | 60.61 | ||||
embB 306+embB 807 | ATG-GTG+AAC-AAG | 1 | 3.03 | |||||
embB 306+embB 563 | ATG-GTG+ATT-CTT | 1 | 3.03 | |||||
embB 306 | ATG-ATC | 5 | 15.15 | |||||
embB 406 | GGC-GCC | 3 | 9.09 | |||||
embB 406 | GGC-TGC | 2 | 6.06 | |||||
embB 1024 | GAC-AAC | 1 | 3.03 | |||||
合计 | 33 | 100.00 | ||||||
利福平 | ropB 531 | TCG-TTG | 26 | 41.27 | ||||
ropB 531+ropB 645 | TCG-TTG+TAC-CAC | 2 | 3.17 | |||||
ropB 531+ropB 367 | TCG-TTG+GCG-GTG | 1 | 1.59 | |||||
ropB 531+ropB 531 | TCG-TTG+TCG-TCT | 1 | 1.59 | |||||
ropB 531+ropB 561 | TCG-TTG+ATC-GTC | 3 | 4.76 | |||||
ropB531+ropB472+ropB915 | TCG-TTG+GAG-CAG+CCG-TCG | 1 | 1.59 | |||||
ropB 531+ropB 584 | TCG-TTG+TTC-TCC | 1 | 1.59 | |||||
ropB 531+ropB 126 | TCG-TTG+CCG-TCG | 1 | 1.59 | |||||
ropB 531+ropB 126 | TCG-TTG+CCG-CTG | 1 | 1.59 | |||||
ropB 522 | TCG-TGG | 3 | 4.76 | |||||
ropB 533 | CTG-CCG | 3 | 4.76 | |||||
ropB 516 | GAC-TAC | 2 | 3.17 | |||||
ropB 126 | CCG-TCG | 1 | 1.59 | |||||
ropB 251 | GTC-TTC | 3 | 4.76 | |||||
ropB 526 | CAC-CGC | 2 | 3.17 | |||||
ropB 526 | CAC-GAC | 4 | 6.35 | |||||
ropB 511 | CTG-CCG | 1 | 1.59 | |||||
ropB 511+ropB 249 | CTG-CCG+GTG-TTG | 2 | 3.17 | |||||
ropB 511+ropB 665 | CTG-CCG+GCC-GGC | 1 | 1.59 | |||||
ropB 511+ropB 516 | CTG-CCG+GAC-GCC | 1 | 1.59 | |||||
ropB 511+ropB 526 | CTG-CCG+CAC-GAC | 1 | 1.59 | |||||
ropB 526+ropB 526 | CAC-CGC+CAC-GAC | 1 | 1.59 | |||||
ropB526+ropB526+ropB526 | CAC-CGC+CAC-GAC+CAC-CAG | 1 | 1.59 | |||||
合计 | 63 | 100.00 | ||||||
药品名称 | 相关基因及位点 | 突变类型 | 突变菌株数 | 突变频率(%) | ||||
链霉素 | rpsL 43 | AAG-AGG | 42 | 79.25 | ||||
rpsL 88 | AAG-AGG | 11 | 20.75 | |||||
合计 | 53 | 100.00 | ||||||
氧氟沙星 | gyrA 94 | GAC-GGC | 16 | 76.19 | ||||
gyrA 90 | GCG-GTG | 2 | 9.52 | |||||
gyrA 91 | TCG-CCG | 2 | 9.52 | |||||
gyrB | GTC-GCC | 1 | 4.77 | |||||
合计 | 21 | 100.00 |
[1] | 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础学组和临床学组. 结核分枝杆菌耐药性检测专家共识. 中国防痨杂志, 2019,41(2):129-137. doi: 10.3969/j.issn.1000-6621.2019.02.003. |
[2] | 张俊仙, 吴雪琼. 结核分枝杆菌耐药性检测方法的研究进展. 中国防痨杂志, 2019,41(2):227-232. doi: 10.3969/j.issn.1000-6621.2019.02.019. |
[3] | 周晛, 艾静文, 崔鹏, 等. 二代测序技术对活动性结核病患者的诊断价值. 中国防痨杂志, 2018,40(2):153-156. doi: 10.3969/j.issn.1000-6621.2018.02.008. |
[4] | 孙照刚, 张洪静, 李自慧, 等. 新一代微测序基因芯片的设计及其耐药性检测效果的初步研究. 中国防痨杂志, 2019,41(6):609-615. doi: 10.3969/j.issn.1000-6621.2019.06.005. |
[5] | 闫雪梅. 结核分枝杆菌耐药机制研究进展. 新疆医科大学学报, 2012,35(2):249-255. doi: 10.3969/j.issn.1009-5551.2012.02.029. |
[6] | Campbell PJ, Morlock GP, Sikes RD, et al. Molecular Detection of Mutations Associated with First- and Second-Line Drug Resistance Compared with Conventional Drug Susceptibility Testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2011,55(5):2032-2041. doi: 10.1128/AA C.01550-10. |
[7] | Engstrom A, Moreillo N, Imperiale B, et al. Detection of first-and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. J Clin Microbiol, 2012,50(6):2026-2033. doi: 10.1007/978-1-4939-2715-9_24. |
[8] | Luo T, Zhao M, LiX, et al. Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob Agents Ch, 2010,54(3):1075-1081. doi: 10.1128/AAC.00964-09. |
[9] |
Anna Engström, Morcillo N, Imperiale B, et al. Detection of First- and Second-Line Drug Resistance in Mycobacterium tuberculosis Clinical Isolates by Pyrosequencing. J Clin Microbiol, 2012,50(6):2026-2033. doi: 10.1128/JCM.06664-11.
URL pmid: 22461677 |
[10] | Brossier F, Veziris N, Aubry A, et al. Detection by Geno Type MTB DRsl test of complex mechanisms of Resistance to Second-line Drugs and Ethambutol in Multidrug-Resistant Mycobacterium tuberculosis Complex Isolates. J Clin Microbiol, 2010,48(5):1683-1689. doi: 10.1128/JCM.01947-09. |
[11] | 陈燕, 赵丽丽, 孙庆, 等. 耐多药结核分枝杆菌耐药相关基因突变特征分析. 疾病监测, 2014,29(4):307-309. doi: 10.3784/j.issn.1003-9961.2014.04.014. |
[12] |
Yuan X, Zhang T, Kawakami K, et al. Molecular characterization of multidrug-and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China. J Clin Microbiol, 2012,50(7):2404-2413. doi: 10.1128/JCM.06860-11.
URL pmid: 22553245 |
[13] | 孙荣, 欧维正, 王燕, 等. 贵阳市结核分枝杆菌链霉素和乙胺丁醇耐药相关基因突变的检测与分析. 中国人兽共患病学报, 2016,32(8):760-764. doi: 10.3969/j.issn.1002-2694.2016.08.015. |
[14] | 张俊仙, 吴雪琼, 邢婉丽, 等. 应用基因芯片技术检测结核分枝杆菌链霉素耐药性的研究. 中国人兽共患病学报, 2009,25(11):1046-1048. doi: 10.3969/j.issn.1002-2694.2009.11.004. |
[15] |
Tracevska T, Jansone I, Nodieva A, et al. Characterisation of rpsL, rrs and embB mutations associated with streptomycin and ethambutol resistance in Mycobacterium tuberculosis. Res Microbiol, 2004,155(10):830-834. doi: 10.1016/j.resmic.2004.06.007.
doi: 10.1016/j.resmic.2004.06.007 URL pmid: 15567277 |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||